Company: INV
Filing Date: 2025-10-23
Form Type: S-1
Source: 0001140361-25-039085
Chunk: 220

Company: Innventure, Inc.
Filing Date: 2025-10-23
Form: S-1
Chunk 220
---
 — |     |                — |
| Outstanding at December 31, 2024 |     |   913,849 |     |         $12.20 |     |            $6.63 |
| Exercisable at December 31, 2024 |     |         — |     |              — |     |                — |

During the Successor period from October 2, 2024 through December 31, 2024, the Company recognized compensation costs related to the stock options of $ 405within General and administrative expense in the consolidated statements of operations and comprehensive income (loss). As of December 31, 2024, the Company had $ 6,063in compensation expense remaining to be recognized over approximately 1.68years. Stock Appreciation Rights On December 31, 2024 the Company granted 350,000stock appreciation rights with respect to the equity of Accelsius Holdings LLC. The SARs were awarded to certain Innventure directors, officers, and former service providers of the Company and its affiliates (the “Participants”). The SARs entitle the Participants to shares of

F-39

TABLE OF CONTENTS

Innventure, Inc. and Subsidiaries Notes to Consolidated Financial Statements (in thousands, except share or per share data) Common Stock, or cash, equal to the value of the appreciation in Accelsius’ stock price over the base price of $ 12.175. TwoParticipants, who were considered non-employees, were granted cash-settled SARs and threeParticipants were granted stock-settled SARs. The cash-settled SARs are considered liability-classified and the stock-settled SARs are considered equity-classified Both the cash-settled SARs and stock-settled SARs will be automatically exercised upon the two-year anniversary of the date of grant. The weighted average contractual term is 2years. The estimated grant date fair value of the cash-settled SARs and the stock-settled SARs was $ 1,160and $ 12,371, respectively. The SARs were valued using the Black-Scholes option-pricing model based on an expected volatility of 70%, an expected term of approximately 2years, and risk-free rate of return of 4%. The SARs are considered fully vested at the date of grant and compensation cost for both SARs was recognized immediately at the date of grant. During the Successor period from October 2, 2024 through